Hepatitis B virus infection

Researchers are testing whether adding a PD-1 antibody and pegylated interferon to standard antiviral pills can help people with chronic hepatitis B lose the hepatitis B surface antigen. The trial enrolls adults whose virus is already suppressed by nucleos(t)ide analogues and who…

This trial investigates whether removing a genetic 'brake' called ANKRD11 can restore the ability of immune cells (T cells) to fight chronic hepatitis B. The approach uses gene editing to create enhanced T cells that may overcome the immune exhaustion that keeps the virus alive. …

This study looks at whether a medicine called peginterferon alfa, alone or with other antivirals, can clear the hepatitis B surface antigen from the blood. A total of 10,000 adults aged 18-65 who have used interferon before and still have low antigen levels will take the treatmen…

This phase 3 trial tests a new combination vaccine called BK1803 in healthy infants aged 2 to 7 months. The vaccine aims to protect against six diseases: whooping cough, diphtheria, tetanus, polio, hepatitis B, and Haemophilus influenzae type b. Researchers compare BK1803 to a st…

This early-stage trial is testing a new drug called ACT500 in 24 people who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will take ACT500 or a placebo daily, and r…

This trial tests whether adding an experimental drug called TQA3605 to standard antiviral therapy helps more adults with chronic hepatitis B reach undetectable virus levels. About 930 participants who have been on antiviral treatment for at least a year will receive either TQA360…

This phase 2 study tests whether the drug bepirovirsen can achieve a functional cure for chronic hepatitis B in 30 adults with low virus levels. Participants receive weekly injections for 24 weeks and undergo liver biopsies to measure changes in the virus and immune response. The…

This early-stage trial tests an injection called TVAX-028 in adults with chronic hepatitis B. The study checks if the drug is safe and how the body processes it. Participants receive either TVAX-028 with an adjuvant or the adjuvant alone, at different dose levels. The goal is to …

This study tests whether a combined approach—offering HIV PrEP (pills or injections) and STI prevention (doxycycline after sex) along with smartphone tools—helps young men at high risk stay protected. About 400 men aged 18-29 who have sex with men will be followed for a year to s…

This early-phase study tests a new injectable drug called AHB-171 in 144 adults with chronic hepatitis B. The main goals are to check the drug's safety and how the body processes it. Some participants will also take standard oral antivirals. The study is not yet recruiting.

This phase 3 trial tests a new drug called GST-HG141 (Nairecovir) combined with standard antivirals in 576 adults with chronic hepatitis B. Participants have already completed 48 weeks of treatment in an earlier study. The goal is to see if the combination is safe and helps keep …

This study tests whether a one-visit, point-of-care test and treat approach helps more people with HIV, hepatitis B, or hepatitis C complete hepatitis C treatment within 24 weeks compared to standard care. About 1,280 participants will be randomly assigned to either the simplifie…

This early-phase study will test whether adding peginterferon alfa-2b to standard antiviral drugs can help prevent hepatitis B-related liver cancer from coming back after surgery. About 156 adults aged 18 to 65 will receive either the combination or antivirals alone. Researchers …

This study tests an AI-powered assistant (Union-Agent) designed to encourage people with chronic hepatitis B who have been diagnosed but not yet treated to start antiviral medication. The study will enroll 2000 adults in China who are eligible for treatment but haven't started. T…

This study tests whether giving two antiviral drugs—entecavir followed by pegylated interferon—can help children aged 3 to 6 with chronic hepatitis B achieve a functional cure (clearing the virus from the blood). About 80 children will be randomly assigned to receive either entec…

This study tests whether adding pegylated interferon to entecavir helps young children (ages 3-6) with chronic hepatitis B achieve a functional cure, meaning the virus becomes undetectable. Sixty children will receive either entecavir alone or entecavir followed by the combinatio…

This Phase 3 trial tests an injection called TVAX-008 for people with chronic hepatitis B. About 630 adults who have been on antiviral therapy for at least 6 months will receive either TVAX-008, a placebo, or an active comparator. The goal is to see if the treatment can clear hep…

This phase 2 trial will enroll 82 stable liver transplant recipients with chronic hepatitis B to see if switching to entecavir orally disintegrating tablets (ETV-ODT) is safe and helps preserve kidney function. Participants will take the drug daily for 48 weeks, and researchers w…

This study will offer free hepatitis B testing to nearly 240,000 adults in Phichit, Thailand, who were born before 1992 and may have been infected before vaccines were available. Those who test positive will receive care and daily medication to control the virus and prevent liver…

This study compares two antiviral strategies—one using a single drug (TAF) and the other starting with two drugs (entecavir plus TAF) then switching to TAF alone—in 120 people with advanced hepatitis B-related liver cancer who are also receiving immunotherapy. The main goal is to…

This study tests whether a weekly injection of pegylated interferon alfa-2b for 48 weeks can help children and teens (ages 3–17) with chronic hepatitis B achieve a functional cure. The treatment group will be compared to an observation group receiving no drug or standard antivira…

This early-stage trial tests a new therapeutic vaccine (Hepadvax) in 40 adults with chronic hepatitis B. The vaccine is designed to boost the immune system to control or possibly clear the virus. Researchers will monitor safety, viral load, and immune responses compared to a stan…

This study tests a new wearable patch-type ultrasound probe that sticks to the skin over the liver to measure stiffness, which can indicate scarring (fibrosis) or cirrhosis. Researchers will compare its accuracy to the standard FibroScan device in 150 adults with chronic liver di…

This study compares a new, more precise digital PCR test with the standard test for measuring hepatitis B virus levels in people with chronic hepatitis B. Researchers will use leftover blood samples from about 200 patients to see if the new method matches the standard test's accu…

This study will test a new rapid device called TruPlex that checks for HIV, Hepatitis B, and Syphilis using a single fingerstick blood sample. About 500 adults at risk for these infections will take part. Researchers want to see if the test is accurate and easy for trained staff …

This study will check if a new device called MagIA H3S can accurately detect HIV, hepatitis B, hepatitis C, and syphilis in pregnant women in the Democratic Republic of the Congo. About 7,500 pregnant women will take part. The goal is to see if this quick test works as well as st…

This study in Zimbabwe will screen women of childbearing age and high school students for HPV and Hepatitis B, then offer vaccines to those who are eligible. It also includes cognitive behavioral therapy for mental health issues. The goal is to see if this combined approach can p…

This study explores whether providing home self-sampling kits for six sexually transmitted infections (STIs) can help sex workers get tested more easily. Participants receive a kit to collect samples at home and return them by mail, along with a questionnaire about their backgrou…

This study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced …

This observational study follows adults in France who are newly diagnosed with chronic hepatitis B (with or without hepatitis D). Researchers will measure liver scarring, treatment eligibility, and viral characteristics to understand how severe the disease is at diagnosis. The go…

This study tests whether a pop-up alert in electronic medical records can help primary care doctors order screening for HIV, hepatitis B, and hepatitis C all at once. About 50 primary care providers will participate, and their patient visits will be randomly assigned to either se…

This study will follow 352 pregnant women with chronic hepatitis B to see how often their liver enzymes rise after giving birth. Researchers want to find out what factors predict these spikes, especially comparing those who took antiviral drugs during pregnancy to those who did n…

This study looks at how the hepatitis B virus changes over time in people taking antiviral drugs. Researchers will analyze blood samples from 700 adults in Turkey to see if the virus becomes resistant to treatment. The goal is to help doctors choose the best medications for each …

This study will follow 5,160 pregnant women in France who have HIV, hepatitis B, hepatitis C, or an arbovirus infection (like Zika or dengue), along with their children, for up to 7 years. Researchers want to learn how these viruses and their treatments affect pregnancy, the moth…

This study will enroll 2,000 Egyptian patients with chronic hepatitis B to find out how common antiviral drug resistance is and what factors make it more likely. Researchers will look at patients taking common antiviral drugs like tenofovir, entecavir, or lamivudine. The goal is …

This study will compare a new handheld device to the standard iLivTouch system for measuring liver stiffness and fat in 224 adults with chronic liver disease. Participants will be tested with both devices while lying down and sitting. The goal is to see if the handheld device is …

This study will screen 1,000 Chinese adults aged 18 to 50 living in Milan for hepatitis B and C using rapid finger-prick tests. Participants get counseling in Italian or Chinese, fill out a short questionnaire, and receive results the same day. The goal is to see if culturally ta…